We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Eli Lilly, Halliburton, Monster Beverage, Huntington Bancshares and Liberty Global
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 11, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Eli Lilly (NYSE:LLY – Free Report), Halliburton (NYSE:HAL – Free Report), Monster Beverage (NASDAQ:MNST – Free Report), Huntington Bancshares (NASDAQ:HBAN – Free Report) and Liberty Global (NASDAQ:LBTYA – Free Report).
Top Research Reports for Eli Lilly, Halliburton & Monster Beverage
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (NYSE:(LLY - Free Report) – Free Report), Halliburton (NYSE:(HAL - Free Report) – Free Report) and Monster Beverage (NASDAQ:(MNST - Free Report) – Free Report). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Pharmaceutical stocks have been under pressure since last year on pricing and regulatory concerns and Eli Lily shares have been no different. That said, the stock has done modestly better than the peer group; it is up +12.2% year to date vs. +10.9% gain for the Zacks Pharma industry and +9.5% increase for the Zacks Medical sector as a whole. Lilly’s second-quarter 2017 results were strong with the company beating estimates on both counts.
The company also raised its sales and earnings outlook for the year. Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been performing well and the trend is expected to continue. The Zacks analyst is encouraged by the fact that Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year.
However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs.
Oil-related stocks have been under pressure this year on stubborn global crude glut and Halliburton shares have been no different. That said, the stock has done better than the peer group; it is down -23.6% in 2017 vs. -31.2% loss for the Zacks Oil Field Services industry.
The world’s No. 2 oilfield-services provider reported strong Q2 profit thanks to improved utilization and pricing gains in North America. Halliburton's 12th consecutive quarterly beat was aided by cost saving initiatives. HAL is also set to gain from the Summit ESP buyout on account of the latter’s expertise in extending the life of shale wells.
However, pricing pressure across the international markets is likely to dampen investor confidence. Moreover, with the failure of the BHI acquisition, HAL had to book a massive $3.5 billion in breakup charges that stretched its balance sheet. Hence, the Zacks analyst thinks investors should wait for a better entry point before buying shares in HAL.
Monster Beverage’s shares have gained +17.4% year to date, outperforming the Zacks Soft Drink industry’s gain of +13.9% during the same period. Monster Beverage’s earnings missed expectations but increased.6% year over year on higher sales. The international segment posted strong results and looks well positioned for the days ahead.
The Zacks analyst likes the fact that the company has several new products lined up for the remaining of 2017 which are likely to boost sales. The company successfully launched or transitioned Monster Energy Drinks to Coca-Cola bottlers in a number of markets in the quarter and expects further transitions and launches in the second half of the year. However, operating expenses continue to rise. Results were also hurt by unfavorable currency rates which dented quarterly net sales.
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Eli Lilly, Halliburton, Monster Beverage, Huntington Bancshares and Liberty Global
For Immediate Release
Chicago, IL – August 11, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Eli Lilly (NYSE:LLY – Free Report), Halliburton (NYSE:HAL – Free Report), Monster Beverage (NASDAQ:MNST – Free Report), Huntington Bancshares (NASDAQ:HBAN – Free Report) and Liberty Global (NASDAQ:LBTYA – Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Eli Lilly, Halliburton & Monster Beverage
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (NYSE:(LLY - Free Report) – Free Report), Halliburton (NYSE:(HAL - Free Report) – Free Report) and Monster Beverage (NASDAQ:(MNST - Free Report) – Free Report). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Pharmaceutical stocks have been under pressure since last year on pricing and regulatory concerns and Eli Lily shares have been no different. That said, the stock has done modestly better than the peer group; it is up +12.2% year to date vs. +10.9% gain for the Zacks Pharma industry and +9.5% increase for the Zacks Medical sector as a whole. Lilly’s second-quarter 2017 results were strong with the company beating estimates on both counts.
The company also raised its sales and earnings outlook for the year. Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been performing well and the trend is expected to continue. The Zacks analyst is encouraged by the fact that Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year.
However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs.
(You canread the full research report on Eli Lilly here >>>).
Oil-related stocks have been under pressure this year on stubborn global crude glut and Halliburton shares have been no different. That said, the stock has done better than the peer group; it is down -23.6% in 2017 vs. -31.2% loss for the Zacks Oil Field Services industry.
The world’s No. 2 oilfield-services provider reported strong Q2 profit thanks to improved utilization and pricing gains in North America. Halliburton's 12th consecutive quarterly beat was aided by cost saving initiatives. HAL is also set to gain from the Summit ESP buyout on account of the latter’s expertise in extending the life of shale wells.
However, pricing pressure across the international markets is likely to dampen investor confidence. Moreover, with the failure of the BHI acquisition, HAL had to book a massive $3.5 billion in breakup charges that stretched its balance sheet. Hence, the Zacks analyst thinks investors should wait for a better entry point before buying shares in HAL.
(You can read the full research report on Halliburton here >>>).
Monster Beverage’s shares have gained +17.4% year to date, outperforming the Zacks Soft Drink industry’s gain of +13.9% during the same period. Monster Beverage’s earnings missed expectations but increased.6% year over year on higher sales. The international segment posted strong results and looks well positioned for the days ahead.
The Zacks analyst likes the fact that the company has several new products lined up for the remaining of 2017 which are likely to boost sales. The company successfully launched or transitioned Monster Energy Drinks to Coca-Cola bottlers in a number of markets in the quarter and expects further transitions and launches in the second half of the year. However, operating expenses continue to rise. Results were also hurt by unfavorable currency rates which dented quarterly net sales.
(You can read the full research report on Monster Beverage here >>>).
Other noteworthy reports we are featuring today include Huntington Bancshares (NASDAQ:(HBAN - Free Report) – Free Report) and Liberty Global (NASDAQ:(LBTYA - Free Report) – Free Report).
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Get the full Report on LLY - FREE
Get the full Report on HAL - FREE
Get the full Report on MNST - FREE
Get the full Report on HBAN - FREE
Get the full Report on LBTYA - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.